FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
|Slideshows|November 13, 2018
Updated AJCC/TNM Staging Better Predictor of Survival in Thyroid Cancer
Author(s)Gregory M. Weiss, MD
The updated staging system results in 36% of patients being reclassified to a lower stage, reducing overdiagnosis.
Advertisement
Evert van Velsen, MD, MSc, and colleagues in the Netherlands have found that the 8th edition of the American Joint Committee on Cancer/Tumor Node Metastasis (AJCC/TNM) staging system is superior to the 7th edition with regards to predicting overall survival (OS) and disease specific survival (DSS) in those with papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC).Click through the slides below for details on their study and take home points for clinical practice.
Advertisement
Related to this article
EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Newly published results from the TRIUMPH-1 study have indicated the direct correlation between the triple agonist and several improvements to weight.
Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
Advertisement
Advertisement
Trending on HCPLive
1
EADV Congress 2026: Day 3 Recap—5 Headlines to Know
2
Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD
3
8 Pulmonology Headlines You Missed in Q3 2026
4
EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis
5